Advertisement

International Journal of Clinical Pharmacy

, Volume 37, Issue 4, pp 555–558 | Cite as

Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients

  • Barbara O. M. ClausEmail author
  • Sylvia Snauwaert
  • Filomeen Haerynck
  • Sabine Van Daele
  • Frans De Baets
  • Petra Schelstraete
Case Report

Abstract

Case description The use of i.v. colistin reappeared recently for the treatment of multidrug-resistant Gram negative organisms in the intensive care and cystic fibrosis (CF) setting. According to the latest pharmacokinetic data, a loading dose and high antibiotic doses are given. Two cases of adverse events (paraesthesias, bad taste) were observed immediately after the start of infusion of a high dose of i.v. colistin in adult CF patients at the Ghent University Hospital. Conclusion Recommendations for optimal administration of i.v. colistin in adult CF patients are scarce. This article highlights the importance of mode of administration to avoid toxicity and relates it to recent pharmacokinetic/-dynamic literature.

Keywords

Administration ADR Adverse drug reaction Colistin Cystic fibrosis Intravenous Neurotoxicity 

Notes

Acknowledgments

We acknowledge Professor William Couet, Poitiers, France, for his valuable reflection on the possibility to assess pharmacokinetic information.

Funding

None.

Conflicts of interest

None.

References

  1. 1.
    Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Plachouras D, Karvanen M, Friberg LE, Friberg LE, Papadomichelakis E, Antoniadou A, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430–6.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–94.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Grégoire N, Mimoz O, Mégarbane B, Comets E, Chatelier D, Lasocki S, Gauzit R, Balayn D, Gobin P, Marchand S, Couet W. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rational. Antimicrob Agents Chemother. 2014;58(12):7324–30.Google Scholar
  5. 5.
    Reed MD, Stern RC, O’Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001;41:645–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003;52:987–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci. 1998;20:149–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005;39:15–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Cheah SE, Bulitta JB, Li J, Nation RL. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal. 2014;92:177–82. doi: 10.1016/j.jpba.2014.01.015 Epub 2014 Jan 24.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • Barbara O. M. Claus
    • 1
    Email author
  • Sylvia Snauwaert
    • 2
  • Filomeen Haerynck
    • 3
  • Sabine Van Daele
    • 3
  • Frans De Baets
    • 3
  • Petra Schelstraete
    • 3
  1. 1.Pharmacy DepartmentGhent University HospitalGhentBelgium
  2. 2.Department of Internal MedicineGhent University HospitalGhentBelgium
  3. 3.Cystic Fibrosis Reference CentreGhent University HospitalGhentBelgium

Personalised recommendations